NCI-H508 Xenograft Model Overview
The NCI-H508 xenograft model is derived from a human colorectal carcinoma cell line initially isolated from a metastatic lesion in a 57-year-old male patient. This model is widely used in preclinical studies focused on metastatic colorectal cancer, particularly in cases where the tumor is resistant to conventional chemotherapies. The NCI-H508 xenograft model is characterized by its ability to form solid tumors with a high degree of epithelial differentiation and metastasis potential, providing a relevant system for testing novel anticancer agents, including targeted therapies, immunotherapies, and combination regimens. The model is particularly useful for evaluating drugs that target epithelial-mesenchymal transition (EMT) pathways, metastasis suppression, and tumor angiogenesis in colorectal cancer.
Request a Custom Quote for NCI-H508 Xenograft ModelBiological and Molecular Characteristics
NCI-H508 cells maintain a polygonal epithelial morphology and exhibit strong cell–cell adhesion. The cell line is microsatellite stable (MSS) and carries wild-type KRAS, BRAF, and NRAS alleles, making it responsive to EGFR-targeted therapies such as cetuximab and panitumumab. TP53 is mutated in this model, impairing the normal apoptotic response to DNA damage and allowing for the testing of agents that exploit defective DNA repair pathways. The cells also express moderate to high levels of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), and other colorectal-specific markers. Wnt/β-catenin signaling is active in this model, with β-catenin localized to both the membrane and cytoplasm. These molecular features render NCI-H508 an ideal model for evaluating EGFR inhibition and combination therapies, as well as for studies on EMT and metastasis.
| Characteristic | NCI-H508 Cell Line Profile |
|---|---|
| Tissue of Origin | Colorectal adenocarcinoma (metastatic) |
| KRAS/BRAF/NRAS Status | Wild-type |
| TP53 Status | Mutated |
| MSI Status | Microsatellite stable (MSS) |
| Differentiation Markers | CK20, CEA, E-cadherin |
| Wnt Signaling | Active, β-catenin cytoplasmic/membranous |
In Vivo Model Development and Tumorigenicity
NCI-H508 xenografts are generated through subcutaneous injection of cultured cells into immunodeficient mouse strains, such as athymic nude or NOD/SCID mice. Tumor formation occurs within 10–14 days after inoculation, with tumors typically reaching 700–900 mm³ in volume within 4–6 weeks. The model exhibits reliable growth and predictable tumor kinetics, making it ideal for long-term studies of drug efficacy and metastasis formation. NCI-H508 xenografts are particularly valuable in preclinical models of metastatic colorectal cancer due to their capacity to mimic key features of human tumors, including epithelial differentiation, invasive potential, and metastatic spread. This model also serves as an excellent platform for testing therapies that target metastasis, angiogenesis, or the tumor microenvironment.
Request a Custom Quote for NCI-H508 Xenograft ModelHistopathology and Immunohistochemical Profile
Histological analysis of NCI-H508-derived xenografts reveals moderately differentiated adenocarcinomas with glandular and occasional mucin production. The tumors exhibit epithelial characteristics with columnar cells, basally located nuclei, and an organized structure that closely mimics human colorectal carcinomas. Hematoxylin and eosin (H&E) staining highlights regions of central necrosis and moderate mitotic activity. Immunohistochemistry shows strong positivity for CK20, CEA, and E-cadherin, confirming the epithelial nature of the tumor and its colorectal origin. β-catenin expression is observed in both the cytoplasm and at the membrane, indicative of active Wnt signaling. Additionally, mutant p53 protein is detected in the tumor nuclei, underscoring the mutation-driven dysregulation of apoptosis. The model’s histological and molecular fidelity ensures that it closely reflects human colorectal cancer and its response to therapy.
Preclinical Applications and Drug Response
The NCI-H508 xenograft model is highly relevant for evaluating therapies targeting EGFR signaling in microsatellite-stable (MSS) colorectal cancer. Its wild-type KRAS, BRAF, and NRAS background ensures that the model is responsive to EGFR inhibitors, making it ideal for testing agents like cetuximab and panitumumab, as well as novel combinations with other targeted therapies. The model’s TP53 mutation also makes it suitable for investigating agents that target apoptotic pathways or DNA repair mechanisms. In addition to EGFR-targeted therapies, NCI-H508 xenografts are useful for testing compounds that modulate EMT, tumor invasion, and metastasis, as well as for studying angiogenesis and the tumor microenvironment. The model is also applied in immunotherapy research, particularly in evaluating immune checkpoint inhibitors and strategies designed to enhance anti-tumor immune responses.
Request This Model
To explore the potential of the NCI-H508 xenograft model in your colorectal cancer research or drug development program, contact our scientific team for customized study designs and model access.
Request a Custom Quote for NCI-H508 Xenograft Model